Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

100023

	registered interest
	date	15/10/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Ovarian Cancer
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what steps he is taking to increase early identification of ovarian cancer.
	tabling member constituency	Washington and Sunderland West
	tabling member printed	Mrs Sharon Hodgson
	uin	905561
	answer	answer is ministerial correction date of answer 21/10/2014 answer text <p>We are investing £450 million in earlier diagnosis of cancer, including improving direct general practitioner access to non-obstetric ultrasound to support earlier diagnosis of ovarian cancer.</p><p> </p><p> </p><p> </p><p>Public Health England ran a regional Be Clear on Cancer campaign early in 2014 to raise awareness of the symptoms of ovarian cancer. The findings of the pilot will be evaluated in 2015, and this evidence would inform any decision to move from a regional to national campaign.</p><p> </p> answering member constituency Battersea answering member printed Jane Ellison question first answered 21/10/2014 15:46:38 answering member 3918 label Biography information for Jane Ellison
	tabling member	1521 label Biography information for Mrs Sharon Hodgson

155937

	registered interest
	date	17/11/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Ovarian Cancer
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what assessment he has made of the effectiveness of the implementation of the National Institute for Health and Care Excellence's most recent guidelines for genetic testing for ovarian cancer.
	tabling member constituency	South Down
	tabling member printed	Ms Margaret Ritchie
	uin	214812
	answer	answer is ministerial correction date of answer 20/11/2014 answer text <p>The National Institute for Health and Care Excellence’s clinical guideline on familial breast cancer, published in June 2013, recommends that women with breast or ovarian cancer should be offered genetic testing if their combined BRCA1 and BRCA2 mutation carrier possibility is 10% or more.</p><p> </p><p> </p><p> </p><p>NHS England is considering moving to a lower threshold as part of the annual prioritisation process for funding in 2015-16.</p><p> </p><p><strong> </strong></p><p> </p><p>We intend to raise the matter of genetic testing for ovarian cancer patients with the Health Ministers of Scotland, Wales, and Northern Ireland in our next regular meeting with them.</p><p> </p><p> </p><p> </p><p> </p><p> </p> answering member constituency Battersea answering member printed Jane Ellison grouped question UIN 214783 question first answered 20/11/2014 16:50:39 answering member 3918 label Biography information for Jane Ellison
	tabling member	4130 label Biography information for Baroness Ritchie of Downpatrick

165987

	registered interest
	date	25/11/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Ovarian Cancer
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what proportion of clinical commissioning group budgets is allocated to ovarian cancer research, awareness and prevention in 2014-15.
	tabling member constituency	Leicester East
	tabling member printed	Keith Vaz
	uin	215922
	answer	answer is ministerial correction date of answer 02/12/2014 answer text <p>National Health Service funding has risen in each year of this parliament and is £12.7 billion higher in cash terms in 2014-15 than in 2010-11. Health funding will again grow in real terms in 2015-16, which means an additional £2.1 billion.</p><p> </p><p> </p><p> </p><p>NHS England has responsibility for clinical commissioning group (CCG) allocations and, as a result of Government protecting the overall health budget for NHS England, NHS England has in turn ensured that all CCGs are receiving a funding increase at least matching inflation, as predicted at the time of the announcement, in 2014-15 and 2015-16.</p><p> </p><p> </p><p> </p><p>The funding that CCGs receive is not ring fenced and as such it is up to CCGs at a local level to decide how to allocate their funding in regards to awareness and prevention.</p><p> </p><p> </p><p> </p><p>The Government’s Mandate to NHS England requires it to ensure that the new commissioning system promotes and supports participation by NHS organisations and NHS patients in research funded by both commercial and non-commercial organisations. This includes ensuring payment of treatment costs for NHS patients taking part in research funded by Government and Research Charity partner organisations. The main Government funders of health research are the National Institute for Health Research and the Medical Research Council.</p><p> </p><p><strong> </strong></p><p> </p> answering member constituency Central Suffolk and North Ipswich answering member printed Dr Daniel Poulter grouped question UIN 215919 215920 215921 question first answered 02/12/2014 17:35:29 answering member 3932 label Biography information for Dr Dan Poulter
	tabling member	338 label Biography information for Keith Vaz

171970

	registered interest
	date	05/01/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Ovarian Cancer
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what discussions his Department has had with NHS England on the implementation of BRCA1/2 gene testing for women recently diagnosed with non-mucinous ovarian cancer.
	tabling member constituency	Knowsley
	tabling member printed	Mr George Howarth
	uin	219719
	answer	answer is ministerial correction date of answer 12/01/2015 answer text <p>The National Institute for Health and Care Excellence’s (NICE) clinical guideline on familial breast cancer, published in June 2013, recommends that women with breast or ovarian cancer should be offered genetic testing if their combined BRCA1 and BRCA2 mutation carrier possibility is 10% or more.</p><p> </p><p> </p><p> </p><p>NICE clinical guidelines represent best practice and we expect National Health Service organisations in England to take them fully into account in designing services to meet the needs of their local populations. Clinical guidelines are not subject to the same statutory funding regulation as NICE’s technology appraisals.</p><p> </p><p> </p><p> </p><p>NHS England advises that moving to routine testing at a 10% risk threshold in England would require a significant capacity and funding investment. This would be for the increase needed in genetic testing and associated counselling, and also in other services such as diagnostics - more mammography for example - and other support and preventative treatments such as surgery.</p><p> </p><p> </p><p> </p><p>However, NHS England is considering moving to a lower threshold as part of the annual prioritisation process for funding in 2015-16.</p><p> </p><p> </p><p> </p><p>Departmental officials have raised this issue with NHS England and it will also be raised at a forthcoming Ministerial meeting.</p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p> answering member constituency Battersea answering member printed Jane Ellison grouped question UIN 219720 question first answered 12/01/2015 17:43:11 answering member 3918 label Biography information for Jane Ellison
	tabling member	481 label Biography information for Sir George Howarth

171973

	registered interest
	date	05/01/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Ovarian Cancer
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, if he will take steps to ensure that all women diagnosed with non-mucinous ovarian cancer are offered BRCA1/2 gene testing at the point of diagnosis.
	tabling member constituency	Knowsley
	tabling member printed	Mr George Howarth
	uin	219720
	answer	answer is ministerial correction date of answer 12/01/2015 answer text <p>The National Institute for Health and Care Excellence’s (NICE) clinical guideline on familial breast cancer, published in June 2013, recommends that women with breast or ovarian cancer should be offered genetic testing if their combined BRCA1 and BRCA2 mutation carrier possibility is 10% or more.</p><p> </p><p> </p><p> </p><p>NICE clinical guidelines represent best practice and we expect National Health Service organisations in England to take them fully into account in designing services to meet the needs of their local populations. Clinical guidelines are not subject to the same statutory funding regulation as NICE’s technology appraisals.</p><p> </p><p> </p><p> </p><p>NHS England advises that moving to routine testing at a 10% risk threshold in England would require a significant capacity and funding investment. This would be for the increase needed in genetic testing and associated counselling, and also in other services such as diagnostics - more mammography for example - and other support and preventative treatments such as surgery.</p><p> </p><p> </p><p> </p><p>However, NHS England is considering moving to a lower threshold as part of the annual prioritisation process for funding in 2015-16.</p><p> </p><p> </p><p> </p><p>Departmental officials have raised this issue with NHS England and it will also be raised at a forthcoming Ministerial meeting.</p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p> answering member constituency Battersea answering member printed Jane Ellison grouped question UIN 219719 question first answered 12/01/2015 17:43:11 answering member 3918 label Biography information for Jane Ellison
	tabling member	481 label Biography information for Sir George Howarth

175463

	registered interest
	date	23/01/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Ovarian Cancer
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what analysis his Department has made of the effect the Government's Strategy for UK Life Sciences on the referral of women with ovarian cancer to suitable trial centres in the UK.
	tabling member constituency	Washington and Sunderland West
	tabling member printed	Mrs Sharon Hodgson
	uin	221903
	answer	answer is ministerial correction date of answer 29/01/2015 answer text <p>The Department’s National Institute for Health Research (NIHR) supports and incentivises hospital trusts and clinicians to participate in clinical trials and studies in a number of ways.</p><p> </p><p> </p><p> </p><p>The NIHR clinical research network (CRN) provides infrastructure and resource to enable the national health service to support participation in research across all clinical specialties and the CRN performance management framework measures and encourages such participation. In 2013/14 through the CRN over 99% of NHS trusts participated in CRN portfolio studies and 86% of NHS trusts participated in CRN commercial contract portfolio studies.</p><p> </p><p> </p><p> </p><p>Decisions on how resource is to be distributed is devolved to local clinical research networks and monitored by the NIHR CRN Co-ordinating Centre on behalf of the Department; in some cases resource is provided as funded clinical sessions.</p><p> </p><p> </p><p> </p><p>Patient recruitment to UK CRN trials and studies in ovarian cancer has more than tripled from 398 in 2009/10 to 1,283 in 2013/14.</p><p> </p><p> </p><p> </p><p>The NIHR provides infrastructure for early phase clinical trials in cancer, including ovarian cancer, through its biomedical research centres, and through experimental cancer medicine centres jointly funded with Cancer Research UK.</p><p> </p><p> </p><p> </p><p>Through its training and career development programmes, the NIHR supports clinicians at all stages of their career: integrated clinical and academic training; predoctoral, doctoral and postdoctoral training; and more senior awards. The prestigious NIHR Senior Investigator award provides an additional incentive for the country’s most outstanding clinical researchers. Participation in clinical trials may form part of research undertaken through training and career development awards.</p><p> </p><p> </p><p> </p><p>The NIHR Research Design Service offers advice and support on clinical trial and other research design and methodology to researchers making funding applications and doing research within the health research system.</p><p> </p><p> </p><p> </p><p>The Government’s Mandate to NHS England requires it to ensure that the new commissioning system promotes and supports participation by NHS organisations and NHS patients in research funded by both commercial and non-commercial organisations.</p><p> </p><p> </p><p> </p><p>The Department has made no specific analysis of the effect of the <em>Strategy for UK Life Sciences </em>on the referral of women with ovarian cancer to suitable trials centres in the United Kingdom. As part of the strategy, the Government re-launched an enhanced web-based UK Clinical Trials Gateway. This provides patients and the public with authoritative and accessible information about clinical trials in the UK, including trials in ovarian cancer. The number of visits to the Gateway nearly tripled from just over 60,000 in 2011/12 to nearly 170,000 in 2013/14.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 221894 221904 question first answered 29/01/2015 17:02:53 answering member 4020 label Biography information for George Freeman
	tabling member	1521 label Biography information for Mrs Sharon Hodgson

175464

	registered interest
	date	23/01/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Ovarian Cancer
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what plans he has to improve the participation of women in trials for ovarian cancer treatments.
	tabling member constituency	Washington and Sunderland West
	tabling member printed	Mrs Sharon Hodgson
	uin	221904
	answer	answer is ministerial correction date of answer 29/01/2015 answer text <p>The Department’s National Institute for Health Research (NIHR) supports and incentivises hospital trusts and clinicians to participate in clinical trials and studies in a number of ways.</p><p> </p><p> </p><p> </p><p>The NIHR clinical research network (CRN) provides infrastructure and resource to enable the national health service to support participation in research across all clinical specialties and the CRN performance management framework measures and encourages such participation. In 2013/14 through the CRN over 99% of NHS trusts participated in CRN portfolio studies and 86% of NHS trusts participated in CRN commercial contract portfolio studies.</p><p> </p><p> </p><p> </p><p>Decisions on how resource is to be distributed is devolved to local clinical research networks and monitored by the NIHR CRN Co-ordinating Centre on behalf of the Department; in some cases resource is provided as funded clinical sessions.</p><p> </p><p> </p><p> </p><p>Patient recruitment to UK CRN trials and studies in ovarian cancer has more than tripled from 398 in 2009/10 to 1,283 in 2013/14.</p><p> </p><p> </p><p> </p><p>The NIHR provides infrastructure for early phase clinical trials in cancer, including ovarian cancer, through its biomedical research centres, and through experimental cancer medicine centres jointly funded with Cancer Research UK.</p><p> </p><p> </p><p> </p><p>Through its training and career development programmes, the NIHR supports clinicians at all stages of their career: integrated clinical and academic training; predoctoral, doctoral and postdoctoral training; and more senior awards. The prestigious NIHR Senior Investigator award provides an additional incentive for the country’s most outstanding clinical researchers. Participation in clinical trials may form part of research undertaken through training and career development awards.</p><p> </p><p> </p><p> </p><p>The NIHR Research Design Service offers advice and support on clinical trial and other research design and methodology to researchers making funding applications and doing research within the health research system.</p><p> </p><p> </p><p> </p><p>The Government’s Mandate to NHS England requires it to ensure that the new commissioning system promotes and supports participation by NHS organisations and NHS patients in research funded by both commercial and non-commercial organisations.</p><p> </p><p> </p><p> </p><p>The Department has made no specific analysis of the effect of the <em>Strategy for UK Life Sciences </em>on the referral of women with ovarian cancer to suitable trials centres in the United Kingdom. As part of the strategy, the Government re-launched an enhanced web-based UK Clinical Trials Gateway. This provides patients and the public with authoritative and accessible information about clinical trials in the UK, including trials in ovarian cancer. The number of visits to the Gateway nearly tripled from just over 60,000 in 2011/12 to nearly 170,000 in 2013/14.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 221894 221903 question first answered 29/01/2015 17:02:53 answering member 4020 label Biography information for George Freeman
	tabling member	1521 label Biography information for Mrs Sharon Hodgson

175465

	registered interest
	date	23/01/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Ovarian Cancer
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what steps his Department is taking to improve early diagnosis of ovarian cancer.
	tabling member constituency	Washington and Sunderland West
	tabling member printed	Mrs Sharon Hodgson
	uin	221905
	answer	answer is ministerial correction date of answer 02/02/2015 answer text <p><em>Improving Outcomes: A Strategy for Cancer</em>, published on 12 January 2011, backed by over £750 million, committed over £450 million over the four years up to 2014-15 to achieve earlier diagnosis of cancer, including supporting direct general practitioner (GP) access to key diagnostic tests such as non-obstetric ultrasound to support the diagnosis of ovarian cancer. In 2012, the Department published ‘Direct access to diagnostic tests for cancer: best practice referral pathways for general practitioners’. The guide aims to raise awareness of the symptoms that require urgent referral to specialists and sets out where a direct referral for tests may benefit patients and lead to a faster diagnosis.</p><p> </p><p> </p><p> </p><p>Diagnostic Imaging Dataset collected by NHS England showed that in August 2014, GPs requested almost a quarter of all tests that may have been used to diagnose or discount cancer, under direct access arrangements. Of these, the test with the highest proportion of GP referral was ultrasounds that may have been used to diagnose ovarian cancer (45% of which were requested by GPs).</p><p> </p><p> </p><p> </p><p>The earlier diagnosis money also included some central funding for Be Clear on Cancer (BCOC) campaigns, which aim to raise awareness of the symptoms of cancer and get symptomatic patients to present earlier. Public Health England ran a regional ovarian pilot campaign which ran from 10 February to 16 March 2014 in the North West of England Television region. The campaign was aimed at women over 50, the age group most at risk of developing ovarian cancer, and their friends and family to raise awareness of bloating as a symptom of ovarian cancer and to encourage women with this symptom to visit their GP. Full evaluation results are awaited.</p><p> </p><p> </p><p> </p><p>The National Institute for health and Care Excellence’s most recent guidelines recommend offering genetic testing to people with a 10% risk of carrying a BRCA mutation, which is lower than the 20% risk previously recommended. The draft policy proposal for BRCA testing is amongst those awaiting consultation by NHS England’s Clinical Priorities Advisory Group. This will take place following the 90-day public consultation on the decision-making framework which NHS England will use to make decisions on specialised services proposals, which is now live.</p><p> </p><p> </p><p> </p><p>Following this consultation period, the Clinical Priorities Advisory Group will review the proposal and make a recommendation to the NHS England Specialised Services Committee, who will make a final decision.</p><p> </p><p> </p><p> </p><p>On 11 January NHS England announced a new independent cancer taskforce to develop a five-year action plan for cancer services to improve survival rates and save thousands of lives.</p><p> </p><p> </p><p> </p><p>The taskforce has been set up to produce a new national cancer strategy for the next five years to 2020, building on NHS England’s vision for improving cancer outcomes set out in the NHS Five Year Forward View. The taskforce will be set up in partnership with the cancer community and other health system leaders, and will be chaired by Dr Harpal Kumar, Chief Executive of Cancer Research UK. The new strategy will cover prevention, early and faster diagnosis, better treatment and care for all, recovery, reablement and living with and beyond cancer. The strategy will also cover research and innovation, end-of-life care, data and metrics, and workforce. The taskforce will produce a statement of intent by March 2015, and will aim to publish the new strategy in the summer.</p><p> </p><p> </p><p> </p><p>NHS England also launched a major early-diagnosis programme, working jointly with Cancer Research UK and Macmillan Cancer Support to test new approaches to identifying cancer more quickly. These include offering patients the option to self-refer for diagnostic tests, lowering the threshold for GP referrals, and setting up multi-disciplinary diagnostic centres, so that patients can have several tests done at the same place on the same day. NHS England’s aim is to evaluate these innovative initiatives across more than 60 centres around England, in order to collect evidence on approaches that could be implemented from 2016-17.</p><p> </p><p> </p><p> </p> answering member constituency Battersea answering member printed Jane Ellison question first answered 02/02/2015 17:32:40 answering member 3918 label Biography information for Jane Ellison
	tabling member	1521 label Biography information for Mrs Sharon Hodgson

175466

	registered interest
	date	23/01/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Ovarian Cancer
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, if he will publish the full evaluation report of the Be Clear on Cancer regional pilot for ovarian cancer.
	tabling member constituency	Washington and Sunderland West
	tabling member printed	Mrs Sharon Hodgson
	uin	221893
	answer	answer is ministerial correction date of answer 28/01/2015 answer text <p>Public Health England (PHE) can confirm that there will be a full and final evaluation report for the regional ovarian pilot campaign published as soon as possible, when analysis of all metrics is complete. However, in advance of a final evaluation report, the National Cancer Intelligence Network (part of PHE) aims to publish the results from the analysis of Cancer Waiting Times data for the regional ovarian pilot during the early part of 2015.</p><p> </p> answering member constituency Battersea answering member printed Jane Ellison question first answered 28/01/2015 13:42:49 answering member 3918 label Biography information for Jane Ellison
	tabling member	1521 label Biography information for Mrs Sharon Hodgson

177186

	registered interest
	date	02/02/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Ovarian Cancer
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, if he will meet bodies representing cancer sufferers to discuss the evaluation of the Be Clear on Cancer regional pilot for ovarian cancer.
	tabling member constituency	Pudsey
	tabling member printed	Stuart Andrew
	uin	222849
	answer	answer is ministerial correction date of answer 05/02/2015 answer text <p>For each Be Clear on Cancer campaign there is a comprehensive evaluation process. Data is collected on a number of metrics to reflect the possible campaign impact on key elements of the patient pathway.</p><p> </p><p> </p><p> </p><p>The National Cancer Intelligence Network (part of Public Health England) have confirmed that they will publish a full and final evaluation report for the regional ovarian cancer pilot campaign as soon as possible, when analysis of all metrics is complete. However, in advance of a final evaluation report, they aim to publish an interim report containing the cancer awareness levels and the results from the analysis of Cancer Waiting Times data before the end of February 2015, at which time we will arrange a meeting with Public Health England and ovarian cancer charities to discuss these results.</p><p> </p> answering member constituency Battersea answering member printed Jane Ellison question first answered 05/02/2015 17:49:22 answering member 3918 label Biography information for Jane Ellison
	tabling member	4032 label Biography information for Stuart Andrew